GH3B6 pituitary tumor cell proliferation is mediated by PKCα and PKC via ERK 1/2-dependent pathway

Cellular Physiology and Biochemistry

Volumn 26, Issue 2, 2010, Pages 135-146

  Petiti, Juan Pablo ^a,c   Gutiérrez, Silvina ^a   De Paul, Ana Lucí ^a   Andreoli, Verónica ^b   Palmeri, Claudia Mariela ^a   Sosa, Liliana Del Valle ^a   Bocco, José Luis ^b   Torres, Alicia Inés ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c Haya de la Torre Esq Enrique Barros   (Argentina)

Author keywords

Cell proliferation; ERK 1 2; Pituitary; PKC; PKC

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN KINASE C EPSILON;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL DIVISION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HYPOPHYSIS TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL;

EID: 78049337938     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320519     Document Type: Article

References (55)

1. Melmed S: Mechanisms for pituitary tu-morigenesis: the plastic pituitary. J Clin Invest 2003;112:1603-1618.
2. Vender JR, Laird MD, Dhandapani KM: Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells. Neurosurgery 2008;62:1122-1127.
3. Spada A, Lania A, Mantovani G: Hormonal signaling and pituitary adenomas. Neuroendocrinology 2007;85:101-109.
4. Lania A, Mantovani G, Spada: A Genetics of pituitary tumors: Focus on G-protein mutations. Exp Biol Med (Maywood) 2003;228:1004-1017.
5. Basu A, Sivaprasad U: Protein kinase Cepsilon makes the life and death decision. Cell Signal 2007;19:1633-1642.
6. Yoshida K: PKCdelta signaling: mechanisms of DNA damage response and apoptosis. Cell Signal 2007;19:892-901.
7. Lin YF, Lee HM, Leu SJ, Tsai YH: The essentiality of PKCalpha and PKCbeta (I) translocation for CD14(+)monocyte differentiation towards macrophages and dendritic cells, respectively. J Cell Biochem 2007;102:429-441.
8. Garrido-Gracía JC, Bellido C, Aguilar R, Sanchez-Criado JE: Protein kinase C cross-talk with gonadotrope progesterone receptor is involved in GnRH-induced LH secretion. J Physiol Biochem 2006;62:35-42.
9. Oliva JL, Caino MC, Senderowicz AM, Kazanietz MG: S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells. J Biol Chem 2008;283:5466-5476.
10. Fishman DD, Segal S, Livneh E: The role of protein kinase C in G1 and G2/M phases of the cell cycle (review). Int J Oncol 1998;12:181-186.
11. Ohno S, Nishizuka Y: Protein kinase C isotypes and their specific functions: prologue. J Biochem 2002;132:509-511.
12. MacEwan DJ, Johnson MS, Mitchell R: Protein kinase C isoforms in pituitary cells displaying differential sensitivity to phorbol ester. Mol Cell Biochem 1999;202:85-90.
13. Quittau-Prévostel C, Delaunay N, Collazos A, Vallentin A, Joubert, D: Targeting of PKCalpha and epsilon in the pituitary: a highly regulated mechanism involving a GD (E) E motif of the V3 region. J Cell Sci 2004;117:63-72.
14. Kenessey A, Sullivan EA, Ojamaa K: Nuclear localization of protein kinase C-alpha induces thyroid hormone receptor-alpha1 expression in the cardiomyocyte. Am J Physiol Heart Circ Physiol 2006;290:H381-389.
15. Petiti JP, De Paul AL, Gutiérrez S, Palmeri CM, Mukdsi JH, Torres AI: Activation of PKC epsilon induces lactotroph proliferation through ERK1/2 in response to phorbol ester. Mol Cell Endocrinol 2008;283:77-84.
16. Petiti JP, Gutiérrez S, Mukdsi JH, De Paul AL, Torres AI: Specific subcellular targeting of PKCalpha and PKCepsilon in normal and tumoral lactotroph cells by PMA-mitogenic stimulus. J Mol Histol 2009;40:417-425.
17. Qiu ZH, Leslie CC: Protein kinase C-dependent and-independent pathways of mitogen-activated protein kinase activation in macrophages by stimuli that activate phospholipase A2. J Biol Chem 1994;269:19480-19487.
18. Krishna M, Narang H: The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008;65:3525-3544.
19. Palmeri CM, Petiti JP, Sosa LV, Gutiérrez S, De Paul AL, Mukdsi JH, Torres AI: Bromocriptine induces parapoptosis as the main type of cell death responsible for experimental pituitary tumor shrinkage. Toxicol Appl Pharmacol 2009;240:55-65.
20. Tabet F, Schiffrin EL, Touyz RM: Mi-togen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kinase C-independent pathways in vascular smooth muscle cells: upregulation in spontaneously hypertensive rats. J Hypertens 2005;23:1961-1962.
21. Sriraman V, Modi SR, Bodenburg Y, Denner LA, Urban RJ: Identification of ERK and JNK as signaling mediators on protein kinase C activation in cultured granulosa cells. Mol Cell Endocrinol 2008;294:52-60.
22. Brazil DP, Hemmings BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657-664.
23. Griner EM, Kazanietz MG: Protein Ki-nase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-294.
24. Gorin MA, Pan Q: Protein kinase C ep-silon: an oncogene and emerging tumor biomarker. Mol Cancer 2009;19:8-9.
25. Haughian JM, Bradford AP: Protein ki-nase C alpha (PKCalpha) regulates growth and invasion of endometrial cancer cells. J Cell Physiol 2009; 220: 112-118.
26. Alvaro V, Touraine P, Raisman Vozari R, Bai-Grenier F, Birman P, Joubert D: Protein kinase C activity and expression in normal and adenomatous human pituitaries. Int J Cancer 1992;50:724-730.
27. Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GK, Lopes MB, Laws ER Jr: Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 2007;170:356-365.
28. Tiedemann K, Hussein O, Sadvakassova G, Guo Y, Siegel PM, Komarova SV: Breast cancer derived factors stimulate osteoclastogenesis through the Ca2+ / PKC and TGF-p/MAPK signaling pathways. J Biol Chem 2009;284:33662-33670.
29. Tsai JH, Hwang JM, Ying TH, Shyu JC, Tsai CC, Hsieh YS, Wang YW, Liu JY, Kao SH: The activation of matrix metalloproteinase-2 induced by protein kinase C alpha in decidualization. J Cell Biochem 2009;108:547-54.
30. Eichholtz T, Bont DB, Widt J, Liskamp RM Ploegh HL: A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J Biol Chem 1993;268:1982-1986.
31. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-27494.
32. Oomizu S, Takeuchi S, Takahashi S: Stimulatory effect of insulin-like growth factor I on proliferation of mouse pituitary cells in serum-free culture. J Endocrinol 1998;157:53-62.
33. Gutiérrez S, Petiti JP, De Paul AL, Mukdsi JH, Aoki A, Torres AI, Orgnero EM: Antagonic effects of oestradiol in interaction with IGF-1 on proliferation of lactotroph cells in vitro. Histochem Cell Biol 2005;124:291-301.
34. Kazanietz MG: Novel "nonkinase" phorbol ester receptors: the C1 domain connection. Mol Pharmacol 2002;61:759-767.
35. Fields AP, Gustafson WC: Protein kinase C in disease: cancer. Methods Mol Biol 2003;233:519-537.
36. Ballester R, Rosen OM: Fate of immunoprecipitable protein kinase C in GH3 cells treated with phorbol 12-myristate 13-acetate. J Biol Chem 1985;260:15194-15199.
37. Uht RM, Amos S, Martin PM, Riggan AE, Hussaini IM: The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene 2007;26:2885-2893.
38. Kuriyama M, Taniguchi T, Shirai Y, Sasaki A, Yoshimura A, Saito N: Activation and translocation of PKCdelta is necessary for VEGF-induced ERK activation through KDR in HEK293T cells. Biochem Biophys Res Commun 2004;325:843-851.
39. Sharma GD, Kakazu A, Bazan HE: Protein kinase C alpha and epsilon differentially modulate hepatocyte growth factor-induced epithelial proliferation and migration. Exp Eye Res 2007;85:289-297.
40. Denys A, Hichami A, Maume B, Khan NA: Docosahexaenoic acid modulates phorbol ester-induced activation of extracellular signal-regulated kinases 1 and 2 in NIH/3T3 cells. Lipids 2001;36:813-818.
41. Mackay HJ, Twelves CJ: Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 2007;7:554-562.
42. Rácz GZ, Szucs A, Szlávik V, Vág J, Burghardt B, Elliott AC, Varga G: Possible role of duration of PKC-induced ERK activation in the effects of agonists and phorbol esters on DNA synthesis in Panc-1 cells. J Cell Biochem 2006;98:1667-1680.
43. Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR: A feed-forward loop involving protein ki-nase Calpha and microRNAs regulates or cell cycle. Cancer Res 2009;69:65-74.
44. Quereda V, Malumbres M: Cell cycle control of pituitary development and disease. J Mol Endocrinol 2009;42:75-86.
45. Matsuzaki Y, Takaoka Y, Hitomi T, Nishino H, Sakai T : Activation of protein kinase C promotes human cancer cell growth through downregulation of p18 (INK4c). Oncogene 2004;23:5409-5414.
46. Bae KM, Wang H, Jiang G, Chen MG, Lu L, Xiao L: Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-de-pendent manner. Cancer Res 2007;67:6053-6063.
47. Win HY, Acevedo-Duncan M: Role of protein kinase C-iota in transformed non-malignant RWPE-1 cells and andro-gen-independent prostate carcinoma DU-145 cells. Cell Prolif 2009;42:182-194.
48. Malumbres M, Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-231.
49. Dworakowska D, Grossman AB: The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:525-41.
50. Hamilton HB, Hinton DR, Law RE, Gopalakrishna R, Su YZ, Chen ZH, Weiss MH, Couldwell WT: Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. J Neurosurg 1996;85:329-34.
51. Jin L, Maeda T, Chandler WF, Lloyd RV: Protein kinase C (PKC) activity and PKC messenger RNAs in human pituitary adenomas. Am J Pathol 1993;142:569-578.
52. Alvaro V, Lévy L, Dubray C, Roche A, Peillon F, Quérat B, Joubert D: Invasive human pituitary tumors express a point-mutated alpha-protein kinase-C. J Clin Endocrinol Metab 1993;77:1125-1129.
53. Zhu Y, Dong Q, Tan BJ, Lim WG, Zhou S, Duan W: The PKCalpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals. Cancer Res 2005;65:4520-4524.
54. Mackay HJ, Twelves CJ: Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer 2003;10:389-396.
55. Hanauske AR, Lahn M, Musib LC, Weigang-Köhler K, Yilmaz E, Graefe T, Kuenen B, Thornton D, McNealy P, Giaccone G: Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/meta-static cancer. Ann Oncol 2009;20:1565-1575.